-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Investors One-year Losses Continue as Jiangsu Gdk Biotechnology (SHSE:688670) Dips a Further 9.3% This Week, Earnings Continue to Decline
Investors One-year Losses Continue as Jiangsu Gdk Biotechnology (SHSE:688670) Dips a Further 9.3% This Week, Earnings Continue to Decline
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active investors aim to buy stocks that vastly outperform the market - but in the process, they risk under-performance. For example, the Jiangsu gdk Biotechnology Co., Ltd. (SHSE:688670) share price is down 49% in the last year. That's disappointing when you consider the market declined 13%. Jiangsu gdk Biotechnology hasn't been listed for long, so although we're wary of recent listings that perform poorly, it may still prove itself with time. The falls have accelerated recently, with the share price down 14% in the last three months.
Since Jiangsu gdk Biotechnology has shed CN¥379m from its value in the past 7 days, let's see if the longer term decline has been driven by the business' economics.
Check out our latest analysis for Jiangsu gdk Biotechnology
While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.
Unhappily, Jiangsu gdk Biotechnology had to report a 45% decline in EPS over the last year. We note that the 49% share price drop is very close to the EPS drop. Given the lower EPS we might have expected investors to lose confidence in the stock, but that doesn't seemed to have happened. Rather, the share price is remains a similar multiple of the EPS, suggesting the outlook remains the same.
You can see how EPS has changed over time in the image below (click on the chart to see the exact values).
SHSE:688670 Earnings Per Share Growth September 15th 2022It might be well worthwhile taking a look at our free report on Jiangsu gdk Biotechnology's earnings, revenue and cash flow.
A Different Perspective
We doubt Jiangsu gdk Biotechnology shareholders are happy with the loss of 48% over twelve months (even including dividends). That falls short of the market, which lost 13%. There's no doubt that's a disappointment, but the stock may well have fared better in a stronger market. The share price decline has continued throughout the most recent three months, down 14%, suggesting an absence of enthusiasm from investors. Basically, most investors should be wary of buying into a poor-performing stock, unless the business itself has clearly improved. It's always interesting to track share price performance over the longer term. But to understand Jiangsu gdk Biotechnology better, we need to consider many other factors. Case in point: We've spotted 2 warning signs for Jiangsu gdk Biotechnology you should be aware of, and 1 of them is a bit unpleasant.
For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on CN exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
被动投资指数基金是确保你自己的回报与整体市场大致匹配的好方法。积极投资者的目标是买入表现远远好于大盘的股票--但在这个过程中,他们面临表现不佳的风险。例如,江苏广德科生物科技有限公司。(上海证券交易所:688670)去年股价下跌了49%。当你考虑到市场下跌了13%时,这是令人失望的。江苏广发生物科技上市时间不长,因此,尽管我们对近期表现不佳的上市持谨慎态度,但随着时间的推移,它可能仍会证明自己。股价最近加速下跌,在过去三个月里下跌了14%。
由于江苏广发生物科技在过去7天里市值缩水3.79亿元人民币,让我们看看长期下跌是否受到了企业经济的推动。
查看我们对江苏广德科生物科技的最新分析
虽然市场是一种强大的定价机制,但股价反映的是投资者情绪,而不仅仅是潜在的企业表现。评估围绕一家公司的情绪变化的一个有缺陷但合理的方法是将每股收益(EPS)与股价进行比较。
令人遗憾的是,江苏广发生物科技去年不得不报告每股收益下降了45%。我们注意到,49%的股价跌幅与每股收益的跌幅非常接近。考虑到较低的每股收益,我们可能预计投资者会对该股失去信心,但这似乎并没有发生。相反,该公司股价仍接近每股收益的倍数,这表明前景保持不变。
您可以在下图中看到EPS是如何随着时间的推移而变化的(单击图表可查看精确值)。
上海证交所:2022年9月15日每股收益增长688670也许很值得一看我们的免费江苏广德科生物科技的收益、收入和现金流报告。
不同的视角
我们怀疑江苏广发生物科技的股东对过去12个月亏损48%(甚至包括股息)感到满意。这一数字低于大盘,大盘下跌13%。毫无疑问,这令人失望,但在一个更强劲的市场中,该股很可能表现得更好。最近三个月,股价持续下跌,跌幅达14%,表明投资者缺乏热情。基本上,大多数投资者应该对买入表现不佳的股票保持警惕,除非业务本身已经明显改善。跟踪股价的长期表现总是很有趣的。但要更好地理解江苏广德科生物科技,我们还需要考虑许多其他因素。一个恰当的例子:我们发现了江苏GDK生物技术的2个警示标志你应该知道,其中一个是有点令人不快的。
对于那些想要找到赢得投资这免费最近有内幕收购的不断增长的公司名单可能就是合适的选择。
请注意,本文引用的市场回报反映了目前在CN交易所交易的股票的市场加权平均回报。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧